Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:CUE NASDAQ:GANX NASDAQ:ME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$3.35-28.4%$1.85$0.40▼$5.48$56.89M0.37349,340 shs1.43 million shsCUECue Biopharma$0.80+1.6%$0.69$0.45▼$1.99$59.98M1.43403,210 shs115,807 shsGANXGain Therapeutics$1.77$1.85$0.89▼$3.19$53.00M0.12295,588 shs320,322 shsME23andMe$0.50-35.3%$0.50$0.53▼$10.81$13.36M1.191.49 million shs29.28 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma-1.27%+50.97%+188.89%+345.71%+513.61%CUECue Biopharma+6.86%+13.19%+22.97%+8.97%-15.77%GANXGain Therapeutics+5.36%+8.26%-7.33%+12.03%+50.00%ME23andMe0.00%0.00%0.00%0.00%-94.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVCABVC BioPharma0.4805 of 5 stars0.03.00.00.02.50.80.0CUECue Biopharma4.066 of 5 stars3.52.00.04.72.40.80.6GANXGain Therapeutics2.8175 of 5 stars3.65.00.00.01.90.00.6ME23andMeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 0.00N/AN/AN/ACUECue Biopharma 3.00Buy$3.00280.71% UpsideGANXGain Therapeutics 3.17Buy$8.20360.67% UpsideME23andMe 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ME, ABVC, CUE, and GANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/19/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$508.38K112.57N/AN/A$0.06 per share56.17CUECue Biopharma$7.99M7.43N/AN/A$0.28 per share2.81GANXGain TherapeuticsN/AN/AN/AN/A$0.28 per shareN/AME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$4.90M-$0.13N/A∞N/A-963.46%-29.62%-14.08%8/13/2025 (Estimated)CUECue Biopharma-$40.67M-$0.67N/AN/AN/A-507.87%-228.43%-114.66%8/13/2025 (Estimated)GANXGain Therapeutics-$20.41M-$0.86N/AN/AN/AN/A-247.55%-146.06%8/6/2025 (Estimated)ME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ALatest ME, ABVC, CUE, and GANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025GANXGain Therapeutics-$0.16-$0.16N/A-$0.16$0.03 millionN/A5/12/2025Q1 2025CUECue Biopharma-$0.14-$0.17-$0.03-$0.17$0.90 million$0.42 million4/30/2025Q4 2024ABVCABVC BioPharmaN/A-$0.06N/A-$0.06N/AN/A4/15/2025Q4 2024ABVCABVC BioPharmaN/A$0.04N/A$0.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.220.22CUECue BiopharmaN/A1.031.03GANXGain Therapeutics0.052.222.22ME23andMeN/A1.050.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%CUECue Biopharma35.04%GANXGain Therapeutics11.97%ME23andMe36.10%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma17.10%CUECue Biopharma10.78%GANXGain Therapeutics7.18%ME23andMe26.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3016.98 million14.08 millionNot OptionableCUECue Biopharma6075.35 million67.23 millionOptionableGANXGain Therapeutics2029.95 million27.80 millionOptionableME23andMe77026.83 million19.77 millionNot OptionableME, ABVC, CUE, and GANX HeadlinesRecent News About These CompaniesEast Bay startup led by former 23andMe exec snags $54.5 million to target deadly kidney diseaseJuly 10 at 12:30 PM | bizjournals.comNorth Carolina secured privacy of 23andMe customersJuly 9 at 9:25 PM | msn.com23andMe customers advised to submit deletion requests before another company buys DNA dataJuly 9 at 2:25 AM | kutv.comKSnapchat Parent Company Takes Over Former 23andMe Lease in SunnyvaleJuly 8 at 8:24 PM | bisnow.comB23andMe Privacy Reviewer Defends WilmerHale as Choice of CounselJuly 8 at 8:24 PM | news.bloomberglaw.comNHealthcare Dealmakers—Ascension's $3.9B ASC push, 23andMe returning to Wojcicki and moreJuly 8 at 3:22 PM | fiercehealthcare.comFJudge briefly pauses 23andMe bankruptcy sale amid California's appealJuly 8 at 3:22 PM | reuters.com23andMe Judge Denies California Bid to Pause State Data TransferJuly 8 at 10:21 AM | news.bloomberglaw.comNBankruptcy judge approves 23andMe sale; what happens to your data?July 8 at 10:21 AM | msn.comCalifornia fails to stop 23andMe founder from re-acquiring companyJuly 8 at 10:21 AM | msn.comCalifornia to appeal judge's approval of 23andMe sale to former CEO Anne WojcickiJuly 5, 2025 | bizjournals.com23andMe's Data Breach Settlement Could Net You Free Money: Here's HowJuly 5, 2025 | cnet.comSnap takes over 23andMe’s former offices in SunnyvaleJuly 4, 2025 | therealdeal.comTCalifornia Appeals 23andMe Genetic Data Sale in Bankruptcy CaseJuly 4, 2025 | news.bloomberglaw.comNCourt approves sale of 23andMe to non-profit led by genetic company’s co-founder and ex-CEO — What Canadian customers should knowJuly 2, 2025 | orangeville.comO23andMe's new owner says your DNA is safe this timeJuly 2, 2025 | msn.comAttorney General Todd Rokita secures protections for Hoosiers’ DNA amid 23andMe bankruptcyJuly 2, 2025 | wbiw.comW23andMe Co-Founder Anne Wojcicki Wins Back Company In $305M Deal, Beating Regeneron’s BidJuly 2, 2025 | msn.comJudge approves 23andMe sale to nonprofit led by Anne WojcickiJuly 2, 2025 | medtechdive.comMATTORNEY GENERAL: 23andMe genetic data to be managed by nonprofit research instituteJuly 2, 2025 | msn.comAnne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million...July 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerDon’t Miss These 2 Small Quantum Stocks Poised to PopBy Gabriel Osorio-Mazilli | June 24, 2025View Don’t Miss These 2 Small Quantum Stocks Poised to Pop3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedME, ABVC, CUE, and GANX Company DescriptionsABVC BioPharma NASDAQ:ABVC$3.35 -1.33 (-28.42%) Closing price 04:00 PM EasternExtended Trading$3.34 0.00 (-0.15%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Cue Biopharma NASDAQ:CUE$0.80 +0.01 (+1.62%) Closing price 04:00 PM EasternExtended Trading$0.77 -0.03 (-3.14%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Gain Therapeutics NASDAQ:GANX$1.77 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.83 +0.06 (+3.39%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.